Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131
暂无分享,去创建一个
[1] Jung-Hyun Yang,et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. , 2004, Thyroid : official journal of the American Thyroid Association.
[2] Y. Choi,et al. Prevalence of Thyroid Cancer at a Medical Screening Center: Pathological Features of Screen-detected Thyroid Carcinomas , 2008, Yonsei medical journal.
[3] S. Purisch,et al. Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity , 2008, Journal of Nuclear Medicine.
[4] M. Tempero,et al. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] A. Introduction. RELEASE OF PATIENTS ADMINISTERED RADIOACTIVE MATERIALS , 1997 .
[6] S. Janković,et al. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. , 2009, Thyroid : official journal of the American Thyroid Association.
[7] Carlos D Venencia,et al. Hospital discharge of patients with thyroid carcinoma treated with 131I. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] M. Schlumberger,et al. 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.
[9] M. Pacilio,et al. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements , 2005, Nuclear medicine communications.
[10] M. O'Doherty,et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid , 1997, European Journal of Nuclear Medicine.
[11] C. Bal,et al. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. , 2006, Radiation protection dosimetry.